Latest Metastasectomy Stories
CALGARY, Feb. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX: ONC) (NASDAQ: ONCY) announced today that enrollment has been completed in a U.K.
BRUSSELS, August 19, 2010 /PRNewswire/ -- Using the innovative technique of radioembolisation to treat patients with inoperable colorectal cancer liver metastases who have failed all standard-of-care chemotherapy options can more than double the time until their disease progresses, according to the final results of a Phase III randomised controlled trial published in the prestigious Journal of Clinical Oncology.(1) The prospective, randomised trial compared a protracted infusion of...
Esophageal carcinoma (EC) is one of the major malignant diseases worldwide.
Preliminary research suggests that criteria based on computed tomography (CT) imaging of changes in tumors from colorectal liver metastases after chemotherapy with the drug bevacizumab may have the potential to predict overall survival.
Using routine computed tomography (CT) imaging to analyze form and structural changes to colorectal liver metastasis after bevacizumab and chemotherapy may predict overall survival.
A national Radiation Therapy Oncology Group (RTOG) study led by a Medical College of Wisconsin Cancer Center physician at Froedtert Hospital in Milwaukee has found that a course of radiation therapy to the brain after treatment for locally advanced non-small cell lung cancer reduced the risk of metastases to the brain within the first year after treatment.
A new study shows that a large majority of patients who present with advanced colorectal cancer that has spread to other organs (stage IV) don't require immediate surgery to remove the primary tumor in the colon.
Randomized, Controlled, Multicenter Trial Will Test Ability of Adecatumumab to Prolong Disease Free Survival in High Risk Patients with Liver Metastases BETHESDA, Md., March 23 /PRNewswire-FirstCall/ -- Micromet, Inc.
CALGARY, Jan. 27 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that patient enrolment has begun in a U.K.
HUNTINGTON BEACH, California and AMSTERDAM, December 12 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint(R)'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr.